- Home
- MLAB
as of 08-21-2026 1:57pm EST
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAKEWOOD |
| Market Cap: | 593.4M | IPO Year: | 1995 |
| Target Price: | $94.00 | AVG Volume (30 days): | 137.8K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 0.49 | EPS Growth: | 436.11 |
| 52 Week Low/High: | $59.63 - $121.90 | Next Earning Date: | 05-27-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6.07% | Revenue Growth (next year): | 5.41% |
| P/E Ratio: | 243.16 | Index: | N/A |
| Free Cash Flow: | 39.6M | FCF Growth: | -11.76% |
Stock Insider Trading Activity of Mesa Laboratories Inc. (MLAB)
Director
Avg Cost/Share
$113.69
Shares
900
Total Value
$102,321.00
Owned After
6,298
SEC Form 4
President and CEO
Avg Cost/Share
$112.80
Shares
7,093
Total Value
$800,090.40
Owned After
7,093
SEC Form 4
Director
Avg Cost/Share
$112.80
Shares
7,093
Total Value
$800,090.40
Owned After
17,834
SEC Form 4
SVP Operations
Avg Cost/Share
$89.50
Shares
2,516
Total Value
$225,187.03
Owned After
6,377
SEC Form 4
CFO
Avg Cost/Share
$89.50
Shares
2,827
Total Value
$253,022.15
Owned After
19,785
SEC Form 4
Avg Cost/Share
$89.50
Shares
442
Total Value
$39,559.88
Owned After
2,020
SEC Form 4
SVP Operations
Avg Cost/Share
$101.27
Shares
1,151
Total Value
$116,558.32
Owned After
6,377
SEC Form 4
CFO
Avg Cost/Share
$101.27
Shares
1,223
Total Value
$123,849.54
Owned After
19,785
SEC Form 4
Avg Cost/Share
$101.27
Shares
118
Total Value
$11,949.51
Owned After
2,020
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tripeny R Tony | MLAB | Director | Aug 13, 2026 | Buy | $113.69 | 900 | $102,321.00 | 6,298 | |
| Kadia Siddhartha | MLAB | President and CEO | Aug 13, 2026 | Buy | $112.80 | 7,093 | $800,090.40 | 7,093 | |
| Sullivan John James | MLAB | Director | Aug 13, 2026 | Sell | $112.80 | 7,093 | $800,090.40 | 17,834 | |
| Archbold Brian David | MLAB | SVP Operations | Jun 22, 2026 | Sell | $89.50 | 2,516 | $225,187.03 | 6,377 | |
| Sakys John | MLAB | CFO | Jun 22, 2026 | Sell | $89.50 | 2,827 | $253,022.15 | 19,785 | |
| Crennen Lyndsey Elizabeth | MLAB | CAO | Jun 22, 2026 | Sell | $89.50 | 442 | $39,559.88 | 2,020 | |
| Archbold Brian David | MLAB | SVP Operations | Jun 16, 2026 | Sell | $101.27 | 1,151 | $116,558.32 | 6,377 | |
| Sakys John | MLAB | CFO | Jun 16, 2026 | Sell | $101.27 | 1,223 | $123,849.54 | 19,785 | |
| Crennen Lyndsey Elizabeth | MLAB | CAO | Jun 16, 2026 | Sell | $101.27 | 118 | $11,949.51 | 2,020 |
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K BUY Aug 10, 2026 · 100% conf.
Q2 2026 Earnings
8-K BUYAug 10, 2026 · 100% conf.
1D
+5.31%
$107.01
Act: +9.46%
5D
+8.58%
$110.34
Act: +5.92%
20D
+7.54%
$109.28
mlab20260807_8k.htm
false 0000724004
0000724004
2026-08-10 2026-08-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): AUGUST 10, 2026
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of incorporation)
0-11740
(Commission File Number)
84-0872291
(I.R.S. Employer Identification No.)
12100 WEST SIXTH AVENUE,
LAKEWOOD, Colorado
(Address of principal executive offices)
80228
(Zip Code)
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which
registered
Common Stock, no par value
MLAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 10, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three months ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits:
99.1
Press release dated August 10, 2026.
104
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: August 10, 2026
Mesa Laboratories, Inc.
(Registrant)
BY:
/s/ John Sakys
John Sakys
Chief Financial Officer
2026 Q1 Q1 2026 Earnings
8-K BUY May 27, 2026 · 100% conf.
Q1 2026 Earnings
8-K BUYMay 27, 2026 · 100% conf.
1D
+4.13%
$94.55
Act: +13.55%
5D
+7.67%
$97.76
Act: +14.96%
20D
+7.46%
$97.58
Act: +8.09%
mlab20260526_8k.htm
false 0000724004
0000724004
2026-05-27 2026-05-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): MAY 27, 2026
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of
incorporation)
0-11740
(Commission File Number)
84-0872291
(I.R.S. Employer
Identification No.)
12100 WEST SIXTH AVENUE,
LAKEWOOD, Colorado
(Address of principal executive offices)
80228
(Zip Code)
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which
registered
Common Stock, no par value
MLAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 27, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and twelve months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits:
99.1
Press release dated May 27, 2026.
104
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: May 27, 2027
Mesa Laboratories, Inc.
(Registrant)
BY:
/s/ John Sakys
John Sakys
Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 3, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 3, 2026 · 100% conf.
1D
+4.06%
$91.08
Act: +4.57%
5D
+8.10%
$94.62
Act: +5.05%
20D
+7.70%
$94.27
Act: +6.06%
mlab20260202_8k.htm
false 0000724004
0000724004
2026-02-03 2026-02-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2026
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Colorado
0-11740
84-0872291
(State or other jurisdiction of
incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
12100 West Sixth Avenue,
Lakewood, Colorado
(Address of principal executive offices)
80228
(Zip Code)
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which
registered
Common Stock, no par value
MLAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On February 3, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and nine months ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits:
99.1
Press release dated February 3, 2026.
104
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: February 3, 2026
Mesa Laboratories, Inc.
(Registrant)
BY:
/s/ Gary M. Owens
Gary M. Owens
President and Chief Executive Officer
Compare MLAB vs Leading Stocks
See how MLAB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MLAB Mesa Laboratories Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.